Clinical Trials
3 trialsNCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01844869 2015-01-30
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed